Federal contract award
75N93022C00060
FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $13.0M |
| Current contract value | $13.0M |
| Potential contract value / ceiling | $20.5M |
| Start date | Sep 21, 2022 |
| Current end date | Dec 31, 2026 |
| Potential end date | Dec 31, 2026 |
| Latest award activity | Sep 11, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 17 of 17 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 11, 2026 | P00016 | $829.0K | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Apr 9, 2026 | P00015 | $1.2M | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Dec 18, 2025 | P00014 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Aug 6, 2025 | P00013 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Jul 1, 2025 | P00012 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| May 5, 2025 | P00011 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Mar 7, 2025 | P00010 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Jan 28, 2025 | P00009 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Nov 4, 2024 | P00008 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Sep 16, 2024 | P00007 | $601.4K | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Jul 31, 2024 | P00006 | $469.4K | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| May 14, 2024 | P00005 | $1.7M | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Mar 29, 2024 | P00004 | $175.0K | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Feb 9, 2024 | P00003 | $3.3M | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Nov 16, 2023 | P00002 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| May 12, 2023 | P00001 | $0 | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
| Sep 21, 2022 | 0 | $4.7M | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2026-12-31 (67 days from calculation)
- +35 points
- 155 historical awards in this buyer and category group
- +15 points
- 17 recorded award transactions
- +10 points
- Latest award action: 2026-09-11
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| George Kennedy | Contact | kennedyg@mail.nih.gov 240-669-5170 | Source | Sep 25, 2020 |
| Tiffany Chadwick | Contact | tiffany.chadwick@nih.gov 240-276-7293 | Source | Sep 25, 2020 |
| George Kennedy | Contact | kennedyg@mail.nih.gov 240-669-5170 | Source | Jul 28, 2020 |
| Tiffany Chadwick | Contact | tiffany.chadwick@nih.gov 240-276-7293 | Source | Jul 28, 2020 |
| George Kennedy | Contact | kennedyg@mail.nih.gov 240-669-5170 | Source | Jul 9, 2020 |
| Tiffany Chadwick | Contact | tiffany.chadwick@nih.gov 240-276-7293 | Source | Jul 9, 2020 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.